Journal of Virology, July 2001, p. 6249-6255, Vol. 75, No. 14
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.14.6249-6255.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Program in Cellular Biotechnology, Institute of Biotechnology, Viikki Biocenter, 00014 University of Helsinki, Finland,1 and Department of Virology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan2
Received 1 February 2001/Accepted 19 April 2001
| |
ABSTRACT |
|---|
|
|
|---|
Hepatitis E virus (HEV), a positive-strand RNA virus, is an
important causative agent of waterborne hepatitis. Expression of cDNA
(encoding amino acids 1 to 979 of HEV nonstructural open reading frame
1) in insect cells resulted in synthesis of a 110-kDa protein (P110), a
fraction of which was proteolytically processed to an 80-kDa protein.
P110 was tightly bound to cytoplasmic membranes, from which it could be
released by detergents. Immunopurified P110 catalyzed transfer of a
methyl group from S-adenosylmethionine (AdoMet) to GTP
and GDP to yield m7GTP or m7GDP. GMP, GpppG,
and GpppA were poor substrates for the P110 methyltransferase. There
was no evidence for further methylation of m7GTP when it
was used as a substrate for the methyltransferase. P110 was also a
guanylyltransferase, which formed a covalent complex, P110-m7GMP, in the presence of AdoMet and GTP, because
radioactivity from both [
-32P]GTP and
[3H-methyl]AdoMet was found in the covalent guanylate
complex. Since both methyltransferase and guanylyltransferase reactions
are strictly virus specific, they should offer optimal targets for
development of antiviral drugs. Cap analogs such as m7GTP,
m7GDP, et2m7GMP, and
m2et7GMP inhibited the methyltransferase
reaction. HEV P110 capping enzyme has similar properties to the
methyltransferase and guanylyltransferase of alphavirus nsP1, tobacco
mosaic virus P126, brome mosaic virus replicase protein 1a, and bamboo
mosaic virus (a potexvirus) nonstructural protein, indicating there is
a common evolutionary origin of these distantly related plant and
animal virus families.
| |
INTRODUCTION |
|---|
|
|
|---|
Hepatitis E virus (HEV) is an important etiological agent of acute epidemic and sporadic enteric hepatitis affecting millions of people mainly in developing countries. The first confirmed HEV epidemic, due to contamination of drinking water in New Delhi, India, was described in 1955. In addition to large epidemics in India and China, there are annually about 2 million sporadic cases of HEV infections in India alone. The mortality among HEV patients has been 0.5 to 4%, except in the case of pregnant women, for whom the average mortality is 20% (for reviews, see references 22 and 33). Recently, closely related viruses have been isolated from pigs, cows, sheep, goats, and rats, indicating zoonotic HEV infections (13).
HEV is a nonenveloped virus with a diameter of 27 to 34 nm (9, 10), which does not replicate in cell cultures (1). The complete nucleotide sequence of the positive-strand RNA genome has been determined for several isolates from different parts of the world (40). (For references, see reference 8.) The HEV genome consists of a 27-nucleotide (nt)-long 5' noncoding region followed by an open reading frame (ORF) coding for a nonstructural protein of 1,693 aa residues. ORF2 starts 38 nt downstream of the termination codon of ORF1 and codes for the capsid protein of 660 aa. ORF3 between nt 5105 and 5476 overlaps with ORF2 and codes for a 123-aa-long polypeptide with unknown function. The 3' noncoding region is 65 nt, ending with a 150- to 200-nt-long poly(A) tail. A recent finding indicates that the HEV genome has an m7G cap structure at the 5' end of the RNA (15).
Expression of HEV capsid protein in COS-1 cells revealed that it is a glycoprotein with a size of 88 kDa, which is synthesized as a precursor (ggPORF2), processed to gPORF2 by cleavage of a signal sequence of 22 aa, and transported to the plasma membrane (14, 46). A more stable cytosolic form of capsid protein PORF2 with a size of 78 kDa has been detected in HepG2 cells by using a Semliki Forest virus (SFV) expression vector (41, 42). So far, which form of capsid protein is responsible for the production of infectious HEV is unknown. A truncated 50-kDa form of PORF2 produced in insect cells is able to assemble into hollow particles with an icosahedral symmetry of T=1 (25, 44). Expression of ORF3 in eukaryotic cells revealed that it is a phosphoprotein with affinity for the cytoskeleton through a hydrophobic amino-terminal domain of 32 aa residues (45).
Expression of complete ORF1 coding for 1,693 aa residues in vitro, in Escherichia coli and in HepG2 cells, resulted in a large 186-kDa protein that was not autocatalytically processed (7). In another study, prolonged in vivo expression yielded N-terminal 78-kDa and C-terminal 107-kDa fragments (34). Transfection of in vitro-synthesized RNA, consisting of the complete HEV genome, to HepG2 cells resulted in synthesis of ORF1, ORF2, and ORF3 products as well as release of small amounts of infectious virus into the culture medium (29). However, no 186-kDa protein was detected in pulse-chase experiments. Instead, region-specific antisera precipitated smaller 35- to 40-kDa polypeptides.
Computer-assisted assignments for the putative functions of HEV ORF1 suggested that the amino-terminal domain from 60 to 240 aa may be a methyltransferase followed by a Y domain with unknown function, a papain-like protease domain (around 440 to 610 aa), a proline-rich spacer region, an X domain of unknown function, a helicase domain (around 960 to 1,200 aa), and an RNA polymerase domain (around 1,200 to 1,700 aa) (17). None of the predicted functions has been experimentally verified. Indeed, it was recently shown that one of the putative protease active site residues is not conserved in different isolates and that mutation of the predicted active site cysteine did not abrogate P186 processing (34). Thus, the predicted protease appears not to exist or have enzymatic activity.
Based on the ORF1 sequence, HEV belongs to a large alphavirus-like superfamily of positive-strand RNA viruses with putative methyltransferase, protease, helicase, and RNA polymerase domains (18). The distinctive methyltransferase domain is the hallmark of the alphavirus-like superfamily (28, 35). It contains sequence similarity to cellular S-adenosylmethionine (AdoMet)-dependent methyltransferases (5). In addition to guanine-7-methyltransferase activity (20, 36), the amino-terminal part of alphavirus nonstructural polyprotein, termed nsP1, also posesses guanylyltransferase activity (2). Both activities are needed in the capping of viral mRNAs (3, 5), and thus the conserved domain can more appropriately be designated as the capping enzyme domain. Both nsP1-catalyzed reactions are virus specific (i.e., there are no known host cell enzymes with similar specificities). Methyltransferase catalyzes the transfer of a methyl group from AdoMet to GTP, resulting in m7GTP, which forms the covalent complex nsP1-m7GMP. These reactions can be inhibited by cap analogs (22).
In the present paper, we show the first enzymatic activity found for the HEV nonstructural protein. Truncated nonstructural protein P110 derived from HEV ORF1 produced in insect cells has virus-specific methyltransferase and guanylyltransferase activities similar to those of alphavirus replicase proteins. This finding provides a novel approach for development of specific inhibitors against hepatitis E infection.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
HEV cDNA constructs. Preparation of a pool of acute-phase stool specimens from patients with sporadic non-A, non-B hepatitis in Myanmar in 1986 and intravenous injection into rhesus monkeys (Macaca mulatta) were described previously (43). After six successive passages in monkeys, bile was collected and used for further study. The total RNA was extracted with RNAzol (Biotecx Laboratories, Inc., Houston, Tex.), and poly(A)-containing RNA was purified with oligotex-dT30 (Super) (Roche Diagnostic Systems, Tokyo, Japan) according to the manufacturer's protocol. RNA was converted into cDNA as described previously (39). The N-terminal 2,964-bp segment of ORF1 was then amplified with primers EP-1 (5'-AGGCAGACCACATATGTGGTCGAT-3') and U-15 (5'-AGCGGGACTTGCCGGATCCAGGCA-3'). The PCR product was cloned into a TA cloning vector, PCRII (Invitrogen, San Diego, Calif.), and digested with the restriction enzymes EcoRI and BamHI, and the resultant ~3-kb fragment was ligated into the transfer vector pVL1392 (Pharmingen, San Diego, Calif.) to yield plasmid pVL [1/2964].
Generation of recombinant baculoviruses. Sf9 cells (Riken Cell Bank, Tsukuba, Japan), derived from Spodoptera frugiperda (31), were cotransfected with linearized wild-type Autographa californica nuclear polyhedrosis virus DNA (Pharmingen) and pVL [1/2964] by the Lipofectin-mediated method as specified by the manufacturer (GIBCO BRL, Gaithersburg, Md.). The cells were incubated at 28°C in TC-100 medium (GIBCO) supplemented with 8% fetal bovine serum and 0.26% Bacto tryptose phosphate broth (Difco Laboratories, Detroit, Mich.). Each recombinant virus was plaque purified three times (38). The baculovirus recombinant thus obtained was designated Ac[1/2964]. In addition to Sf9 cells, we used an insect cell line from Trichoplusia ni, BTL-Tn 5B1-4 (Tn5) (Invitrogen), for protein expression.
Cell fractionation and membrane flotation.
Tn5 cells grown
on petri plates (2 × 106 cells per
35-mm-diameter plate) were infected with Ac-[1/2964] containing cDNA
encoding aa 1 to 979 of HEV ORF1 (hereafter designated as Ac-P110) at
10 PFU/cell. At 44 h postinfection, the cells were collected as
described previously (20). Cells were washed twice with
cold phosphate-buffered saline and once with RS buffer (10 mM Tris-HCl
[pH 8.0], 10 mM NaCl) containing 0.2 mM phenylmethylsulfonyl fluoride
and EDTA-free protease inhibitor cocktail (Boehringer Mannheim GmbH,
Mannheim, Germany). After washes, the cell pellet was resuspended in 5 volumes of RS buffer, left on ice for 15 min to swell, and disrupted in a Dounce homogenizer with 40 strokes. Nuclei were removed by
centrifugation (500 × g for 10 min). Postnuclear
supernatant was subjected to flotation in a sucrose gradient as
described previously (21). The membrane fractions that had
undergone flotation were collected, mixed with TN buffer (50 mM
Tris-HCl [pH 7.5], 100 mM NaCl), and subjected to centrifugation
(70,000 × g for 30 min). The pellet was resuspended in
RS buffer containing 10% glycerol and stored at
80°C.
Enzyme assays.
Methyltransferase activity was assayed in a
final volume of 25 µl containing 100 mM HEPES (pH 7.0), 10 mM GTP, 4 µM AdoMet, 4 mM MnCl2, 2 mM dithiothreitol, and
0.75 µCi of
S-adenosyl[methyl-3H]methionine (88 Ci/mmol; Amersham) for 2 h at 37°C. The reaction was stopped by
adding EDTA to a final concentration of 10 mM. Labeled product was
isolated in small DEAE-Sephadex columns and quantitated by liquid
scintillation as described previously (20). For the
formation of the covalent guanylate complex, 30-µl reaction mixtures
containing 5 µCi of [
-32P]GTP (400 Ci/mmol; Amersham) in 50 mM Tris-HCl (pH 7.5), 10 mM KCl, 2 mM
MgCl2, 5 mM dithiothreitol, and 100 µM AdoMet
were incubated for 20 min at 30°C, as described previously
(2). The reaction was stopped by boiling in the presence
of 1% sodium dodecyl sulfate (SDS). The proteins were separated by
SDS-polyacrylamide gel electrophoresis (PAGE) in 10% polyacrylamide
gels, and the radioactive bands were visualized by autoradiography as
described previously (20).
Radioactive labeling. For palmitate labeling, Tn5 cells infected with Ac-P110 (10 PFU/cell) were labeled at 44 h postinfection with 300 to 400 µCi (per 60-mm-diameter plate) of [9,10(n)-3H]palmitic acid (52 Ci/mmol, Amersham) in Sf-900 II serum-free medium for 8 h at 28°C. For labeling with [35S]methionine, infected cells were incubated in methionine-free Grace medium for 30 min at 28oC and pulse-labeled with 500 µCi (per 100-mm-diameter plate) of [35S]methionine (1,000 Ci/mmol; Amersham) in methionine-free Grace medium for 2 h at 28°C. The cells were chased with 20-fold excess unlabeled methionine for 1 h at 28oC.
Immunological techniques.
For preparation of immune sera,
cDNA encoding aa 1 to 464 (P50) of HEV ORF1 was inserted in plasmid
pBAT (31), which was expressed in E. coli BL21
after induction with 10 µM
isopropyl-
-D-thiogalactopyranoside overnight
at 15°C. After cell breakage with a French press and sedimentation,
the inclusion bodies were washed successively with PBS, 2 M urea, and
PBS followed by solubilization in 0.0625 M Tris-HCl (pH 6.6), 2% SDS,
10% glycerol, and 5% 2-
-mercaptoethanol. After SDS-PAGE, the band
migrating at 50 kDa was eluted in a buffer consisting of 0.1% SDS, 200 mM NaCl, and 50 mM Tris-HCl (pH 7.2). Immunization of two rabbits and
two guinea pigs was carried out exactly as described previously
(19). E. coli-specific antibodies were removed
by passing the sera through a Sepharose column containing covalently
linked bacterial proteins. Furthermore, the antisera were absorbed with
HeLa cells as described previously (19). Immunoprecipitation of protein samples under nondenaturing conditions was done as described previously (32). The
immunoprecipitates were analyzed by SDS-PAGE in 10% polyacrylamide
gels. Western blotting was done as described previously
(20).
| |
RESULTS |
|---|
|
|
|---|
Expression of HEV ORF1 protein P110 in insect cells.
A cDNA
fragment encoding HEV ORF1 aa 1 to 979 (Fig.
1) was cloned under the polyhedrin
promoter of the baculovirus genome as described in Materials and
Methods. Tn5 insect cells were infected with the recombinant
baculovirus at 10 PFU/cell. The expression of HEV-specific ORF1
proteins was monitored at different times after infection in cell
lysates solubilized with SDS. Coomassie blue staining of protein gels
showed a clear band with an apparent molecular mass of about 110 kDa, which first appeared 30 h after infection and increased in
intensity during further incubation (Fig.
2A, lanes 3 to 5). Western blotting with
antiserum against ORF1 aa 1 to 464 (P50), identified the 110-kDa band
as an HEV-specific protein, which was designated P110. Another band
with an apparent molecular mass of 80 kDa (P80) was also detected by
the antiserum (Fig. 2B). The intensity of P80 band was variable,
suggesting that it was a proteolytic cleavage product of P110. This
result resembles that of Ropp et al. (34), who
occasionally observed an N-terminal ORF1 cleavage product with a size
of 78 kDa.
|
|
Methyltransferase and guanylyltransferase activities of P110.
Guanine-7-methyltransferase activity was assayed from postnuclear
supernatant (15,000 × g pellet) and supernatant
fractions of Tn5 cells expressing P110. As a substrate, we used GTP,
and as a methyl donor, we used AdoMet labeled with tritium in the methyl group. Most experiments were carried out with
flotation-treated membranes from Tn5 cells. There was linear
production of m7GTP with respect to time (Fig.
3A). Divalent cations
Mn2+, Mg2+ (Fig. 3B), and
Co2+ (not shown) were essential for the reaction,
but the optimum concentration range was wide, whereas
Ca2+ did not stimulate the reaction. The optimum
pH was 7.25 (Fig. 3C). The methyltransferase of HEV P110 was rather
heat resistant, with a temperature optimum of 42°C (Fig. 3D).
|
-32P]GTP in the presence and absence of
AdoMet followed by immunoprecipitation by anti-HEV (P50) antiserum. The
same reactions were carried out for mock-infected and wild-type
baculovirus-infected Tn5 cell preparations. As a further control, we
used a membrane preparation from recombinant baculovirus-infected cells
expressing SFV capping enzyme nsP1 (data not shown). Before
immunoprecipitation, in preparations containing P110, three radioactive
bands with apparent molecular masses of 110, 80, and 66 kDa were
detected (Fig. 4, lane 1). Of these, the
110- and 80-kDa proteins were detected after immunoprecipitation (Fig.
4, lane 3), indicating that they represented HEV-specific proteins P110
and P80. Labeling of these proteins took place only if AdoMet served as
a methyl donor (Fig. 5), whereas a 66-kDa protein was labeled in the absence of AdoMet in mock-infected (Fig. 4,
lane 5) and in wild-type baculovirus-infected cells (Fig. 4, lane 4).
This protein is evidently the guanylyltransferase of the host cells
(37). The additional band of about 50 kDa, seen in the
baculovirus wild-type-infected cells (Fig. 4, lane 4), most probably
represents the baculovirus-specific guanylyltransferase LEF-4
(12).
|
|
Immunopurified HEV P110.
Treatment of the flotation-treated
membrane fraction with 1% sodium deoxycholate or 1% Triton X-100 did
not inhibit the HEV methyltransferase or guanylyltransferase activities
(data not shown). It was therefore possible to use immunoprecipitation
to obtain enzymatically active P110 preparations. When the P15 fraction of P110-expressing Tn5 cells was subjected to immunoprecipitation with
anti-P50 antiserum, substantial purification of the HEV-specific protein was achieved (Fig. 5, lanes 1 and 2). The purified P110 formed
a covalent complex with [
-32P]GTP, but only
in the presence of AdoMet (Fig. 5, lanes 5 and 6). The recovery of
methyltransferase activity was almost quantitatively and linearly
dependent on the amount of P15 membranes used for immunoprecipitation
(not shown). The finding that a covalent complex between guanosine and
P110 was formed only in the presence of AdoMet suggested that the
reaction took place between P110 and m7GTP rather
than between P110 and GTP. This would imply that the methyl
group from AdoMet should be found in the covalent guanylate-P110 complex. To test this, we carried out the reaction in the presence of
S-adenosyl-L-[methyl-3H]methionine.
P110 was resolved by SDS-PAGE and visualized by phosphoimaging. There
was a clear band migrating at the position of P110 (Fig. 5, lane 9).
The result was confirmed by quantitation of radioactivity from several
parallel gel slices at the position of P110. To obtain evidence that in
synthesis of the covalent complex pyrophosphate was released, we added
PPi in excess to revert the reaction. No covalent
complex was formed in the presence of 800 µM pyrophosphate (Fig. 5,
lanes 7 and 8).
|
Inhibition of the capping enzyme P110.
The inhibitory activity
of some cap analogs on P110 was tested with 3 mM GTP as the methyl
acceptor and the analogs at concentrations of 3 and 0.3 mM (Table
2). As expected,
m7GTP inhibited incorporation of the methyl group
from AdoMet to GTP at both concentrations. m7GDP
was a somewhat better inhibitor, whereas m7GMP
was less efficient. This was in accordance with the properties of GDP
and GMP as substrates for the methyltransferase (Table 1). The
double-substituted guanylate analogs
et2m7GMP and
m2et7GMP had an inhibitory
effect similar to that of m7GMP, but clearly less
than that of m7GDP, suggesting that the
phosphorylation status of the analogs was more important than the
substitutions of the guanylate moiety.
|
| |
DISCUSSION |
|---|
|
|
|---|
Very little is known about the functions of HEV ORF1-encoded
nonstructural protein(s). Since it was shown recently that the virus
RNA has a 5' cap structure (15), we expected that the cap
might be synthesized by virus-encoded enzymes. HEV ORF1 has features in
the amino-terminal region that resemble methyltransferases (5,
17, 35) and guanine-7N-methyltransferase, which is one of the activities needed in RNA capping (37). The
first reaction in the capping of cellular mRNAs is the removal of
-phosphate from the 5' end of nascent RNA molecules by RNA 5'
triphosphatase. In the second reaction, guanylyltransferase reacts with
GTP to make a covalent enzyme-GMP complex releasing pyrophosphate,
followed by a third reaction in which the enzyme-bound GMP is
transferred to the 5' end of the RNA molecule. This unmethylated,
G5'ppp5'N-capped RNA is the substrate in the fourth reaction for the
methyltransferase, which transfers the methyl group from AdoMet to
position 7 of the guanylate, resulting in
m7G5'ppp5'N cap 0 structure (37).
Here we have shown that the HEV ORF1 fragment encoding P110 catalyzes capping reactions that are different from those described above for eukaryotic cells. Like alphaviruses (2), tobacco mosaic virus (TMV) (27), brome mosaic virus (BMV) (1, 16), and bamboo mosaic virus (a potexvirus) (26), HEV P110 instead of methylating unmethylated capped mRNA methylates GTP to form m7GTP, which then reacts to form a covalent enzyme-m7GMP complex. In alphavirus-, TMV-, and BMV-infected cells, both methyltransferase and guanylyltransferase activities are associated with nonstructural proteins nsP1, P126, and 1a, respectively. In the case of HEV, methyltransferase and guanylyltransferase activities were associated with an amino-terminal fragment of the nonstructural ORF1 (979 residues). We failed in our attempts to demonstrate these enzymatic activities for fragments of 470 and 527 residues, suggesting a rather large translational product may be required for enzymatic activity. Therefore, the capping enzyme domain may extend to what was initially predicted to be a protease domain (17), but which appears not to act as a protease (34).
Comparison of the enzymatic properties of HEV P110 with those previously reported for SFV nsP1 (2, 20, 23) and BMV 1a (1) shows that they all are unable to methylate ATP, CTP, UTP, or substrates with a methyl group at position 7 of the guanylate (m7GTP, m7GpppG, m7GpppA, or m7GppppG). In the case of BMV 1a, dinucleotides GpppA and GpppG are severalfold better substrates than GTP, whereas for both SFV nsP1 and HEV P110 methyltransferases, these two dinucleotides are poor substrates. All of these viral enzymes are specific for small acceptor substrates, whereas host methyltransferase involved in the capping of mRNAs methylates only longer GpppN-capped oligonucleotides (37). It is not surprising that the members of this virus-encoded enzyme family show some differences in their in vitro substrate specificity, given that their protein sequences have diverged considerably during evolution (35). The significant in vivo substrate is likely to be GTP, because this is the only nucleotide that after its methylation can form a covalent complex with the enzyme (1, 2) and thereafter be transferred to the RNA acceptor.
Another notable feature of this RNA virus capping enzyme family is that all of its members are membrane associated (1, 21, 26, 27; this study). It has been suggested that the capping enzyme domain might be responsible for the membrane association and targeting of the entire viral RNA replication complex (6). In the case of SFV nsP1, the membrane-binding mechanism has been studied in some detail. First, we found that the tight binding of the capping enzyme to membranes was correlated with the palmitoylation of cysteine residues 418 to 420 of nsP1 (20, 21, 30). However, mutation of cysteines 418 to 420 to alanines did not convert nsP1 to a soluble protein or prevent virus replication in cell cultures (4, 21). Weaker membrane binding of nsP1 was shown to be due to a 20-amino-acid-long amphipathic peptide in the central region of the protein (6, 24).
HEV P110 was tightly membrane-bound, mimicking integral membrane proteins as it is not released by treatments with high salt concentrations, EDTA, or even sodium carbonate at pH 11, all of which are known to release peripheral membrane proteins (11). P110 lacks continuous apolar sequences typical for transmembrane segments of integral membrane proteins. Our attempts to show that P110 is palmitoylated gave negative results. Thus, the mechanism of membrane binding of HEV P110 has to be solved by more extensive analysis, such as that used for SFV nsP1 (6).
Interactions with lipids and detergents in vitro also reveal differences between the viral capping enzymes. Interaction with anionic lipids is essential for the methyltransferase and guanylyltransferase activities of nonpalmitoylated nsP1, suggesting that membrane binding affects the conformation of the protein. All detergents interfere with the enzymatic activities of nonpalmitoylated nsP1 (6). In contrast, the activities of BMV 1a and bamboo mosaic virus capping enzyme have been studied in the presence of detergents (1, 26), and HEV P110 is active in the presence of sodium deoxycholate and Triton X-100 (this study). The precise mechanism of membrane association and its effects on the enzyme activities of these proteins need to be established.
Although the sequence homologies between alphavirus, BMV, and HEV methyl- and guanylyltransferases could be revealed only by advanced bioinformatic methods, they have highly similar enzymatic properties. The demonstration that five distantly related virus families (tobamoviruses, bromoviruses, potexviruses, alphaviruses, and HEV) within the alphavirus-like superfamily have functionally identical RNA capping steps suggests strongly that these reactions are to be found within all members of the superfamily. This would imply that these viruses have a common evolutionary origin, as predicted by sequence comparisons by Koonin and Dolja (18). The biochemical evidence presented in this study establishes HEV as a member of the alphavirus-like superfamily.
Most importantly, both the methyltransferase and guanylyltransferase reactions are virus specific and therefore offer targets for designing novel inhibitors of virus replication. This is especially significant in the case of HEV, because it is a major human pathogen. Due to the similarity of the methyltransferase and guanylyltransferase reactions within the alphavirus-like superfamily, it may even be possible to design compounds with broad-spectrum antiviral properties.
| |
ACKNOWLEDGMENTS |
|---|
We thank Airi Sinkko and Tarja Välimäki for excellent technical assistance and Anja Lampio for valuable advice.
This study was supported by The Academy of Finland (grant no. 8397) and by the Technology Development Centre (TEKES). It was also supported in part by a grant for study of non-A, non-B hepatitis, Research on Emerging and Re-emerging Infectious Diseases, Health Sciences Research grants, and the Ministry of Health and Welfare, Japan. L.K. is a Biocentrum Helsinki fellow, and T.L. is an expert of the Scientific Research on Priority Areas of the Science and Technology Agency, Japan.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Institute of Biotechnology, Viikki Biocenter, PO Box 56 (Viikinkaari 9), 00014 University of Helsinki, Finland. Phone: 358-9-19159400. Fax: 358-9-191 59560. E-mail: leevi.kaariainen{at}helsinki.fi.
Present address: Pfizer Global Research and Development, Sandwich,
Kent, United Kingdom.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Ahola, T., and P. Ahlquist.
1999.
Putative RNA capping activities encoded by brome mosaic virus: methylation and covalent binding of guanylate by replicase protein 1a.
J. Virol.
73:10061-10069 |
| 2. |
Ahola, T., and L. Kääriäinen.
1995.
A unique reaction in alphavirus mRNA capping: formation of a covalent complex of nonstructural protein nsP1 with 7-methyl-GMP.
Proc. Natl. Acad. Sci. USA
92:507-511 |
| 3. |
Ahola, T.,
J. A. den Boon, and P. Ahlquist.
2000.
Helicase and capping enzyme active site mutations in brome mosaic virus protein 1a cause defects in template recruitment, negative-strand synthesis, and viral mRNA capping.
J. Virol.
74:8803-8811 |
| 4. |
Ahola, T.,
P. Kujala,
M. Tuittila,
T. Blom,
P. Laakkonen,
A. Hinkkanen, and P. Auvinen.
2000.
Effects of palmitoylation of replicase protein nsP1 on alphavirus infection.
J. Virol.
74:6725-6733 |
| 5. | Ahola, T., P. Laakkonen, H. Vihinen, and L. Kääriäinen. 1997. Critical residues of Semliki Forest virus RNA capping enzyme involved in methyltransferase and guanylyltransferase-like activities. J. Virol. 71:392-397[Abstract]. |
| 6. | Ahola, T., A. Lampio, P. Auvinen, and L. Kääriäinen. 1999. Semliki Forest virus mRNA capping enzyme requires association with anionic membrane phospholipids for activity. EMBO J. 18:3164-3172[CrossRef][Medline]. |
| 7. | Ansari, I. H., S. K. Nanda, H. Durgapal, S. Agrawal, S. K. Mohanty, D. Gupta, S. Jameel, and S. K. Panda. 2000. Cloning, sequencing, and expression of the hepatitis E virus (HEV) nonstructural open reading frame 1 (ORF1). J. Med. Virol. 60:275-283[CrossRef][Medline]. |
| 8. | Arankalle, V. A., S. Paranjape, S. U. Emerson, R. H. Purcell, and A. M. Walimbe. 1999. Phylogenetic analysis of hepatitis E virus isolates from India (1976-1993). J. Gen. Virol. 80:1691-1700[Abstract]. |
| 9. | Balayan, M. S., A. G. Andjaparidze, S. S. Savinskaya, E. S. Ketiladze, D. M. Braginsky, A. P. Savinov, and V. F. Poleschuk. 1983. Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. Intervirology 20:23-31[Medline]. |
| 10. |
Bradley, D.,
A. Andjaparidze,
E. H. Cook,
K. McCaustland, Jr.,
M. Balayan,
H. Stetler,
O. Velazquez,
B. Robertson,
C. Humphrey, and M. Kane.
1988.
Aetiological agent of enterically transmitted non-A, non-B hepatitis.
J. Gen. Virol.
69:731-738 |
| 11. |
Chong, L. D., and J. K. Rose.
1993.
Membrane association of functional vesicular stomatitis virus matrix protein in vivo.
J. Virol.
67:407-414 |
| 12. |
Gross, C. H., and S. Shuman.
1998.
RNA 5' triphosphatase, nucleoside triphosphatase, and guanylyltransferase activities of baculovirus LEF-4 protein.
J. Virol.
72:10020-10028 |
| 13. |
Favorov, M.,
J. Drobeniuc,
M. Kosoy,
J. Childs,
C. Shapiro,
E. Mast,
B. Robertson, and H. Margolis.
2000.
Hepatitis E an emerging zoonotic disease.
Antivir. Ther.
5:19[Medline].
|
| 14. | Jameel, S., M. Zafrullah, M. H. Ozdener, and S. K. Panda. 1996. Expression in animal cells and characterization of the hepatitis E virus structural proteins. J. Virol. 70:207-216[Abstract]. |
| 15. |
Kabrane-Lazizi, Y.,
X.-J. Meng,
R. H. Purcell, and S. Emerson.
1999.
Evidence that the genomic RNA of hepatitis E virus is capped.
J. Virol.
73:8848-8850 |
| 16. | Kong, F., K. Sivakumara, and C. Kao. 1999. The N-terminal half of the Brome mosaic virus 1a protein has RNA capping-associated activities: specificity for GTP and S-adenosylmethionine. Virology 259:200-210[CrossRef][Medline]. |
| 17. |
Koonin, E. V.,
A. E. Gorbalenya,
M. A. Purdy,
M. N. Rozanov,
G. R. Reyes, and D. W. Bradley.
1992.
Computer-assisted assignment of functional domains in the nonstructural polyprotein of hepatitis E virus: delineation of an additional group of positive-strand RNA plant and animal viruses.
Proc. Natl. Acad. Sci. USA
89:8259-8263 |
| 18. | Koonin, E. V., and V. V. Dolja. 1993. Evolution and taxonomy of positive-strand RNA virus: implication of comparative analysis of amino acid sequences. Crit. Rev. Biochem. Mol. Biol. 28:375-430[Medline]. |
| 19. |
Kujala, P.,
T. Ahola,
N. Ehsani,
P. Auvinen,
H. Vihinen, and L. Kääriäinen.
1999.
Intracellular distribution of rubella virus nonstructural protein P150.
J. Virol.
73:7805-7811 |
| 20. | Laakkonen, P., M. Hyvönen, J. Peränen, and L. Kääriäinen. 1994. Expression of Semliki Forest virus nsP1-methyltransferase in insect cells and in Escherichia coli. J. Virol. 68:7417-7425. |
| 21. | Laakkonen, P., T. Ahola, and L. Kääriäinen. 1996. The effects of palmitoylation on membrane association of Semliki Forest virus capping enzyme nsP1. J. Biol. Chem. 271:7418-7425. |
| 22. |
Labrique, A. B.,
D. L. Thomas,
S. K. Stoszek, and K. E. Nelson.
1999.
Hepatitis E: an emerging infectious disease.
Epidemiol. Rev.
21:162-179 |
| 23. | Lampio, A., T. Ahola, E. Darzynkiewicz, J. Stepinski, M. Jankowska-Anyzska, and L. Kääriäinen. 1999. Guanosine nucleotide analogs as inhibitors of alphavirus mRNA capping enzyme. Antivir. Res. 42:35-46[CrossRef][Medline]. |
| 24. |
Lampio, A.,
I. Kilpeläinen,
S. Pesonen,
K. Karhi,
P. Auvinen,
P. Somerharju, and L. Kääriäinen.
2000.
Membrane-binding mechanism of an RNA virus capping enzyme.
J. Biol. Chem.
275:37853-37859 |
| 25. | Li, T.-C., Y. Yamakawa, K. Suzuki, M. Tatsumi, M. A. Razak, T. Uchida, N. Takeda, and T. Miyamura. 1997. Expression and self-assembly of empty virus-like particles of hepatitis E virus. J. Virol. 71:7207-7213[Abstract]. |
| 26. |
Li, Y. I.,
Y.-J. Chen,
Y.-H. Hsu, and M. Meng.
2001.
Characterization of the AdoMet-dependent guanylyltransferase activity that is associated with the N terminus of bamboo mosaic virus replicase.
J. Virol.
75:782-788 |
| 27. | Merits, A., R. Kettunen, K. Mäkinen, A. Lampio, P. Auvinen, L. Kääriäinen, and T. Ahola. 1999. Virus-specific capping of tobacco mosaic virus RNA: methylation of GTP prior to formation of covalent complex p126-m7GMP. FEBS Lett. 455:45-48[CrossRef][Medline]. |
| 28. | Mi, S., R. Durbin, H. V. Huang, C. M. Rice, and V. Stollar. 1989. Association of the Sindbis virus RNA methyltransferase activity with the nonstructural protein nsP1. Virology 170:385-391[CrossRef][Medline]. |
| 29. |
Panda, S. K.,
I. H. Ansari,
H. Durgapal,
S. Agrawal, and S. Jameel.
2000.
The in vitro-synthesized RNA from a cDNA clone of hepatitis E virus is infectious.
J. Virol.
74:2430-2437 |
| 30. | Peränen, J., P. Laakkonen, M. Hyvönen, and L. Kääriäinen. 1995. The alphavirus replicase protein nsP1 is membrane-associated and has affinity to endocytic organelles. Virology 208:601-620[CrossRef][Medline]. |
| 31. | Peränen, J., M. Rikkonen, M. Hyvönen, and L. Kääriäinen. 1996. T7 vectors with a modified T7 lac promoter for expression of proteins in Escherichia coli. Anal. Biochem. 236:371-373[CrossRef][Medline]. |
| 32. |
Peränen, J.,
K. Takkinen,
N. Kalkkinen, and L. Kääriäinen.
1988.
Semliki Forest virus-specific nonstructural protein nsP3 is a phosphoprotein.
J. Gen. Virol.
69:2165-2178 |
| 33. | Purcell, R. H. 1996. Hepatitis E virus, p. 2831-2843. In B. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, Pa. |
| 34. | Ropp, S. L., A. W. Tam, B. Beames, M. Purdy, and T. Frey. 2000. Expression of the hepatitis E ORF1. Arch. Virol. 145:1321-1337[CrossRef][Medline]. |
| 35. |
Rozanov, M. N.,
E. V. Koonin, and A. E. Gorbalenya.
1992.
Conservation of the putative methyltransferase domain: a hallmark of the "Sindbis-like" supergroup of positive-strand RNA viruses.
J. Gen. Virol.
73:2129-2134 |
| 36. | Scheidel, L., R. K. Durbin, and V. Stollar. 1989. SVLM21, a Sindbis virus mutant resistant to methionine deprivation, encodes an altered methyltransferase. Virology 173:408-414[CrossRef][Medline]. |
| 37. | Shuman, S. 1995. Capping enzyme in eukaryotic mRNA synthesis. Prog. Nucleic Acid Res. Mol. Biol. 50:101-129[Medline]. |
| 38. | Stewart, L. M. D., and R. D. Possee. 1993. Baculovirus expression vectors, p. 227-256. In A. J. Davison, and R. M. Elliotts (ed.), Molecular virology: a practical approach IRL Press, Oxford, United Kingdom. |
| 39. | Supanaranond, K., N. Takeda, and S. Yamazaki. 1992. The complete nucleotide sequence of a variant of coxsackievirus A24. Virus Genes 6:149-158[CrossRef][Medline]. |
| 40. | Tam, A. W., P. O. Yarbough, and D. W. Bradley. 1999. Hepatits E virus, p. 669-676. In A. Granoff, and R. G. Webster (ed.), Encyclopedia of virology, 2nd ed. Academic Press, New York, N.Y. |
| 41. | Torresi, J., J. Meanger, P. Lambert, F. Li, S. A. Locarnini, and D. A. Anderson. 1997. High-level expression of the capsid protein of hepatitis E virus in diverse eukaryotic cells using the Semliki Forest virus replicon. J. Virol. Methods 69:81-91[CrossRef][Medline]. |
| 42. | Torresi, J., F. Li, S. A. Locarnini, and D. A. Anderson. 1999. Only the non-glycosylated fraction of hepatitis E virus capsid (open reading frame 2) protein is stable in mammalian cells. J. Gen. Virol. 80:1185-1188[Abstract]. |
| 43. | Uchida, T., K. M. Win, K. Suzuki, K. Komatsu, F. Iida, T. Shikata, K. Mizuno, S. Soe, H. Myint, K. M. Tin, and K. Nakane. 1990. Serial transmission of a putative causative virus of enterically transmitted non-A, non-B hepatitis to Macaca fascicularis and Macaca mulatta. Jpn. J. Exp. Med. 40:13-21. |
| 44. | Xing, L., K. Kato, T. Li, N. Takeda, T. Miuamura, L. Hammar, and R. H. Cheng. 1999. Recombinant hepatitis E capsid protein self-assembles into dual-domain T=1 particles presenting native virus isotopes. Virology 265:35-45[CrossRef][Medline]. |
| 45. | Zafrullah, M., M. H. Ozdener, S. K. Panda, and S. Jameel. 1997. The ORF3 protein of hepatitis E virus is a phosphoprotein that associates with the cytoskeleton. J. Virol. 71:9045-9053[Abstract]. |
| 46. |
Zafrullah, M.,
M. H. Ozdener,
R. Kumar,
S. K. Panda, and S. Jameel.
1999.
Mutational analysis of glycosylation, membrane translocation, and cell surface expression of the hepatitis E virus ORF2 protein.
J. Virol.
73:4074-4082 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|